Long-term data shows promise in breast cancer biosimilar

22nd March 2019 Uncategorised 0

The a three-year follow-up study comparing Ontruzant to Herceptin has found the biosimilar to be just as successful.

More: Long-term data shows promise in breast cancer biosimilar
Source: News